Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Scoping Review from 2009 to 2022

• Principais autores: Laura Torres-Canchala (Autor), Daniela Cleves-Luna (Autor), Oriana Arias-Valderrama (Autor), Estephania Candelo (Autor), María Angelica Guerra (Autor), Harry Pachajoa (Autor), Manuela Olaya (Autor)
• Formato: Livro
• Publicado em: MDPI AG, 2022-12-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. Objective: This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB...